Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2023-04-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2023. It includes details about the board meeting approval, independent directors' opinions, transaction amounts for 2022 and 2023 estimates, related parties involved, pricing policies, and the impact of these transactions on the company. The document is relatively short (2974 characters) and focuses on disclosure of related party transactions rather than presenting comprehensive financial statements or detailed financial performance. It is not an annual or interim report, nor an earnings release or management discussion. It is a regulatory announcement about expected related party transactions, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance disclosure.
2023-04-10 Chinese
哈药集团股份有限公司2022年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and conclusions about the effectiveness of internal controls related to financial reporting and non-financial reporting. It also includes statements of responsibility from the board and management. The document is not an announcement of a report publication but the report itself, containing substantive evaluation and analysis of internal controls. This type of document aligns with an Audit Report / Information (AR) category, as it is a standalone report on internal control evaluation and audit opinions, not a full annual report or interim financial report. The document length is under 5,000 characters but contains detailed substantive content, so it is not a mere announcement. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-10 Chinese
哈药集团股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by 哈药集团股份有限公司. It references specific accounting standards and interpretations issued by the Ministry of Finance of China, detailing the nature and impact of the accounting policy changes. The document explicitly states it is an announcement and does not contain financial statements or detailed financial data. It is relatively short (2234 characters) and serves to inform shareholders and the public about the policy change rather than presenting a full financial report. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Annual Report, Interim Report, or Audit Report.
2023-04-10 Chinese
哈药集团股份有限公司2022年度内部控制审计报告
Regulatory Filings
2023-04-10 Chinese
哈药集团股份有限公司2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, governance, environmental and social responsibility, and audited financial statements. The document is lengthy (15,000 characters) and includes signatures from company officers and auditors, indicating it is the full official annual report. It also references the audit report as part of the document but is not a standalone audit report. The content matches the description of an Annual Report (10-K) which covers company activity and full financial performance for the fiscal year 2022. Therefore, the correct classification is Annual Report (10-K). FY 2022
2023-04-10 Chinese
哈药集团股份有限公司九届十八次监事会决议公告
Board/Management Information Classification · 90% confidence The document is a resolution announcement from the Supervisory Board of Harbin Pharmaceutical Group Co., Ltd. It details the approval of the 2022 Annual Report, Supervisory Board work report, financial budget, profit distribution plan, asset impairment provisions, internal control reports, and other governance matters. The document is relatively short (1454 characters) and serves as an official announcement of the Supervisory Board's decisions and opinions on the annual report and related matters. It does not contain the full annual report or detailed financial statements but rather the Supervisory Board's review and approval of these items. Therefore, it is not the Annual Report (10-K) itself but an announcement related to governance and supervisory board decisions. Given the content focuses on supervisory board resolutions and governance oversight, the best fitting category is Board/Management Information (MANG).
2023-04-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.